Resolution regarding appropriation of the company's profit according to the adopted balance sheet
The Board of Directors resolved at the Annual General Meeting to allocate the Company's earnings in accordance with the Board's proposal in the annual report.

The meeting resolved in accordance with the Board's proposal that no dividend be paid for the financial year 2024.

Resolution on discharge from liability for the members of the Board of Directors and the CEO
The meeting resolved to discharge the members of the Board of Directors and the Managing Director from liability for the financial year 2024.

Determination of the number of members of the Board of Directors and the number of auditors
The meeting resolved that the Board of Directors shall consist of five ordinary members and no deputy members. The Meeting resolved that one auditor and no deputy auditor shall be appointed.

Determination of fees for the Board of Directors and the auditors
The meeting resolved that the Chairman of the Board shall be paid a fee of SEK 250,000 and the remaining ordinary Board members shall each be paid SEK 125,000. The meeting further resolved that fees to the auditor shall be paid in accordance with approved invoices in accordance with customary billing standards.

Election of Board Members and auditors or auditing firm
The meeting resolved to re-elect Peter Max as a member of the Board of Directors and to elect Lena Höglund, Veronica Byfield, Thomas Binzer and Jerker Nygren. Peter Max was re-elected as Chairman of the Board.

The general meeting resolved to elect Dillon AB as the company's auditor, with Oskar Kantoft as auditor-in-charge, until the end of the annual general meeting to be held in the next financial year.

Resolution on instructions for the Nomination Committee

The meeting resolved, in accordance with the nomination committee's proposal, to adopt instructions for the nomination committee as set out in the presented proposal. The complete proposal can be found in the notice to the 2025 annual general meeting published on 27 May 2025.

The Board's proposal for a resolution authorizing the Board to decide on new share issues
The meeting resolved, in accordance with the Board of Directors' proposal, to authorize the Board of Directors, during the period until the next Annual General Meeting, to decide on the issue of a maximum number of shares, convertibles and/or warrants that entitle to subscription of, or entail the issue of, a maximum number of shares that fall within the limits of the Articles of Association, with or without deviation from the shareholders' preferential rights. The authorization may be exercised on one or more occasions and the Board of Directors shall be entitled to decide on the detailed terms of the issue on each occasion. In addition to cash payment, payment may also be made in kind or by set-off, or otherwise with conditions.  

In order for the company's current shareholders not to be disadvantaged in relation to the external investor or investors who may subscribe for shares in the company, the Board of Directors considers it appropriate that the issue with deviation from the shareholders' preferential rights shall be made at the Board's market-based subscription price, subject to a market-based issue discount where applicable.

Complete documents relating to the Annual General Meeting are available on the Company's website, www.clinicallaser.se.

The information was submitted for publication through the agency of the contact person stated below on June 27, 2025

For more information about CLS, please contact:

Dan J Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40

E-mail: dan.mogren@clinicallaser.com

Website: www.clinicallaser.se

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

About CLS

Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG® Thermal Therapy System and ClearPoint Prism® Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold through partners for image-guided laser ablation and are used in studies for treatment with imILT®, the company's interstitial laser thermotherapy for immune stimulating ablation with potential abscopal treatment effect. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se